BiotechTube

Uridine

Phase 2Completed
0 watching 0 views this week⚡ Active
49
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Bipolar Depression

Conditions

Bipolar Depression

Trial Timeline

Mar 1, 2006 → —

NCT ID
NCT00322764

About Uridine

Uridine is a phase 2 stage product being developed by Repligen for Bipolar Depression. The current trial status is completed. This product is registered under clinical trial identifier NCT00322764. Target conditions include Bipolar Depression.

Hype Score Breakdown

Clinical
17
Activity
12
Company
7
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT00322764Phase 2Completed

Competing Products

20 competing products in Bipolar Depression

See all competitors
ProductCompanyStageHype Score
OlanzapineEli LillyPhase 3
77
Valproate + Lithium + Risperidone + OlanzapineEli LillyPhase 3
77
Olanzapine + PlaceboEli LillyApproved
85
FK949EAstellas PharmaPhase 3
77
FK949EAstellas PharmaPhase 3
77
FK949E + PlaceboAstellas PharmaPhase 2/3
65
Escitalopram + Bupropion XLLupin LimitedPhase 3
77
OlanzapineEli LillyApproved
85
Olanzapine Hydrochloride + Lithium CarbonateEli LillyPhase 3
77
olanzapine + lithium + valproate + carbamazepineEli LillyPhase 3
77
OlanzapineEli LillyApproved
85
OlanzapineEli LillyPhase 3
77
LY2979165 + PlaceboEli LillyPhase 1
33
olanzapine + divalproex sodium + placeboEli LillyApproved
85
olanzapine + risperidoneEli LillyApproved
85
LY2979165 + placeboEli LillyPhase 1
33
Topiramate + PlaceboEli LillyApproved
85
olanzapineEli LillyPhase 3
77
Olanzapine + PlaceboEli LillyPhase 3
77
Brenipatide + PlaceboEli LillyPhase 2
52

Other Products from Repligen

RG1068 (Synthetic Human Secretin)Phase 3
74
RG1068 (Synthetic Human Secretin)Phase 3
74
RG1068 (synthetic human secretin)Phase 3
74
RG1068 (Synthetic Human Secretin)Phase 2
49
RG2417 + PlaceboPhase 2
49